MA30690B1 - Triazolyle phenyle benzenesulfonamides - Google Patents
Triazolyle phenyle benzenesulfonamidesInfo
- Publication number
- MA30690B1 MA30690B1 MA31566A MA31566A MA30690B1 MA 30690 B1 MA30690 B1 MA 30690B1 MA 31566 A MA31566 A MA 31566A MA 31566 A MA31566 A MA 31566A MA 30690 B1 MA30690 B1 MA 30690B1
- Authority
- MA
- Morocco
- Prior art keywords
- ccr2
- ccr9
- compounds
- antagonists
- assays
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
Abstract
L'INVENTION CONCERNE DES COMPOSÉS SUSCEPTIBLES D'AGIR COMME DE PUISSANTS ANTAGONISTES DU RÉCEPTEUR CCR2 OU CCR9. DES ESSAIS SUR DES ANIMAUX DÉMONTRENT L'UTILILTÉ DE CES COMPOSÉS POUR LE TRAITEMENT D'INFLAMMATIONS, UNE MALADIE CARACTÉRISTIQUE POUR CCR2 ET CCR9. CES COMPOSÉS SONT GÉNÉRALEMENT DES DÉRIVÉS D'ARYLSULFONAMIDE QUE L'ON UTILISE DANS DES COMPOSITIONS PHARMACEUTIQUES, DES PROCÉDÉS DE TRAITEMENT DE MALADIES MÉDIÉES PAR CCR2, CCR9, COMME TÉMOINS DANS DES DOSAGES POUR L'IDENTIFICATION D'ANTAGONISTES DE CCR2 ET POUR L'IDENTIFICATION D'ANTAGONISTES DE CCR9.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83104206P | 2006-07-14 | 2006-07-14 | |
US94583907P | 2007-06-22 | 2007-06-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA30690B1 true MA30690B1 (fr) | 2009-09-01 |
Family
ID=38896161
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA31566A MA30690B1 (fr) | 2006-07-14 | 2009-01-12 | Triazolyle phenyle benzenesulfonamides |
Country Status (22)
Country | Link |
---|---|
EP (1) | EP2046762B1 (fr) |
JP (1) | JP5266219B2 (fr) |
KR (1) | KR101433392B1 (fr) |
AT (1) | ATE498615T1 (fr) |
AU (1) | AU2007275873B2 (fr) |
BR (1) | BRPI0714407A2 (fr) |
CA (1) | CA2657776C (fr) |
CO (1) | CO6180465A2 (fr) |
DE (1) | DE602007012552D1 (fr) |
DK (1) | DK2046762T3 (fr) |
EA (1) | EA015710B1 (fr) |
HK (1) | HK1135091A1 (fr) |
IL (1) | IL196409A (fr) |
MA (1) | MA30690B1 (fr) |
MX (1) | MX2009000395A (fr) |
NO (1) | NO341949B1 (fr) |
NZ (1) | NZ574759A (fr) |
PL (1) | PL2046762T3 (fr) |
PT (1) | PT2046762E (fr) |
UA (1) | UA98304C2 (fr) |
WO (1) | WO2008010934A2 (fr) |
ZA (1) | ZA200900281B (fr) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101511800B (zh) | 2006-07-14 | 2013-02-27 | 坎莫森特里克斯公司 | 三唑基苯基苯磺酰胺 |
CN101679319B (zh) | 2007-02-08 | 2014-07-09 | 辛塔医药品有限公司 | 用于治疗增生性病症如癌症的三唑类化合物 |
TWI490214B (zh) * | 2008-05-30 | 2015-07-01 | 艾德克 上野股份有限公司 | 苯或噻吩衍生物及該等作為vap-1抑制劑之用途 |
CA2729767A1 (fr) * | 2008-07-07 | 2010-01-14 | Fasgen, Inc. | Nouveaux composes, compositions pharmaceutiques les contenant, et leurs procedes d'utilisation et de preparation |
WO2011082271A2 (fr) | 2009-12-30 | 2011-07-07 | Arqule, Inc. | Composés triazolo-pyrimidine substitués |
AU2012209295B2 (en) * | 2011-01-25 | 2016-06-30 | The Regents Of The University Of Michigan | Bcl-2/Bcl-xL inhibitors and therapeutic methods using the same |
CN103813793A (zh) * | 2011-07-22 | 2014-05-21 | 葛兰素史克知识产权开发有限公司 | 4-叔丁基-n-[4-氯-2-(1-氧基-吡啶-4-羰基)-苯基]-苯磺酰胺钠盐的多晶型 |
RU2607514C2 (ru) * | 2011-07-22 | 2017-01-10 | Хемоцентрикс, Инк. | Полиморфные формы натриевой соли 4-трет-бутил-n-[4-хлор-2-(1-окси-пиридин-4-карбонил)-фенил]-бензолсульфонамида |
PT2748146T (pt) * | 2011-07-22 | 2017-05-29 | Chemocentryx Inc | Forma cristalina do sal de sódio de 4-terc-butil-n-[4-cloro- 2-(1-oxi-piridina-4-carbonil)-fenil]-benzenossulfonamida |
WO2013060865A1 (fr) | 2011-10-28 | 2013-05-02 | Galderma Research & Development | Nouveaux marqueurs d'infiltrat leucocytaire de rosacée et utilisations de ceux-ci |
ES2645617T3 (es) * | 2012-02-29 | 2017-12-07 | Chemocentryx, Inc. | Pirazol-1-il benceno sulfonamidas como antagonistas del CCR9 |
WO2013130962A1 (fr) | 2012-03-01 | 2013-09-06 | Allergan, Inc. | Dérivés de benzofuran-2-sulfonamide comme modulateurs de récepteurs de chimiokine |
US9340509B2 (en) * | 2013-12-02 | 2016-05-17 | Chemocentryx, Inc. | CCR6 compounds |
JP2017501145A (ja) * | 2013-12-23 | 2017-01-12 | ノージン ビーブイ | Ccr9調節因子として有用な化合物 |
EP3087074A1 (fr) | 2013-12-23 | 2016-11-02 | Norgine BV | Benzène-sulfonamides à titre d'inhibiteurs de ccr9 |
US11872217B2 (en) | 2019-07-10 | 2024-01-16 | Chemocentryx, Inc. | Indanes as PD-L1 inhibitors |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
US5120643A (en) | 1987-07-13 | 1992-06-09 | Abbott Laboratories | Process for immunochromatography with colloidal particles |
US6159686A (en) | 1992-09-14 | 2000-12-12 | Sri International | Up-converting reporters for biological and other assays |
US5514555A (en) | 1993-03-12 | 1996-05-07 | Center For Blood Research, Inc. | Assays and therapeutic methods based on lymphocyte chemoattractants |
US6322901B1 (en) | 1997-11-13 | 2001-11-27 | Massachusetts Institute Of Technology | Highly luminescent color-selective nano-crystalline materials |
US6207392B1 (en) | 1997-11-25 | 2001-03-27 | The Regents Of The University Of California | Semiconductor nanocrystal probes for biological applications and process for making and using such probes |
US5990479A (en) | 1997-11-25 | 1999-11-23 | Regents Of The University Of California | Organo Luminescent semiconductor nanocrystal probes for biological applications and process for making and using such probes |
US6306610B1 (en) | 1998-09-18 | 2001-10-23 | Massachusetts Institute Of Technology | Biological applications of quantum dots |
US6326144B1 (en) | 1998-09-18 | 2001-12-04 | Massachusetts Institute Of Technology | Biological applications of quantum dots |
US6251303B1 (en) | 1998-09-18 | 2001-06-26 | Massachusetts Institute Of Technology | Water-soluble fluorescent nanocrystals |
US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
US7468253B2 (en) | 2001-06-07 | 2008-12-23 | Chemocentryx, Inc. | Method for multiple chemokine receptor screening for antagonists using RAM assay |
DE60216606T2 (de) | 2001-06-07 | 2007-04-05 | Chemocentryx Inc., Mountain View | Zellwanderungsassay |
EP2402310A1 (fr) | 2002-05-24 | 2012-01-04 | Millennium Pharmaceuticals, Inc. | Inhibiteurs de CCR9 et leurs procédés dýutilisation |
US7420055B2 (en) | 2002-11-18 | 2008-09-02 | Chemocentryx, Inc. | Aryl sulfonamides |
CN101077867B (zh) * | 2002-11-18 | 2012-10-10 | 坎莫森特里克斯公司 | 芳基磺酰胺 |
JO2397B1 (en) * | 2002-12-20 | 2007-06-17 | ميرك شارب اند دوم كوربوريشن | Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors |
EP1643960A2 (fr) | 2003-07-02 | 2006-04-12 | Merck & Co., Inc. | Derives arylsulfonamide |
US20090048301A1 (en) * | 2003-07-09 | 2009-02-19 | Imclone Systems Incorporated | Heterocyclic compounds and their use as anticancer agents |
WO2005113513A2 (fr) * | 2004-05-12 | 2005-12-01 | Chemocentryx | Sulfonamides aryle |
US9715915B2 (en) | 2014-10-30 | 2017-07-25 | Samsung Electronics Co., Ltd. | Magneto-resistive devices including a free layer having different magnetic properties during operations |
-
2007
- 2007-07-10 PL PL07836049T patent/PL2046762T3/pl unknown
- 2007-07-10 DE DE602007012552T patent/DE602007012552D1/de active Active
- 2007-07-10 EA EA200900168A patent/EA015710B1/ru not_active IP Right Cessation
- 2007-07-10 AT AT07836049T patent/ATE498615T1/de active
- 2007-07-10 PT PT07836049T patent/PT2046762E/pt unknown
- 2007-07-10 BR BRPI0714407-5A patent/BRPI0714407A2/pt not_active Application Discontinuation
- 2007-07-10 MX MX2009000395A patent/MX2009000395A/es active IP Right Grant
- 2007-07-10 CA CA2657776A patent/CA2657776C/fr active Active
- 2007-07-10 JP JP2009520765A patent/JP5266219B2/ja active Active
- 2007-07-10 EP EP07836049A patent/EP2046762B1/fr active Active
- 2007-07-10 WO PCT/US2007/015808 patent/WO2008010934A2/fr active Application Filing
- 2007-07-10 AU AU2007275873A patent/AU2007275873B2/en active Active
- 2007-07-10 DK DK07836049.2T patent/DK2046762T3/da active
- 2007-07-10 NZ NZ574759A patent/NZ574759A/en not_active IP Right Cessation
- 2007-07-10 KR KR1020097001415A patent/KR101433392B1/ko active IP Right Grant
- 2007-10-07 UA UAA200901182A patent/UA98304C2/uk unknown
-
2009
- 2009-01-08 IL IL196409A patent/IL196409A/en active IP Right Grant
- 2009-01-12 MA MA31566A patent/MA30690B1/fr unknown
- 2009-01-13 ZA ZA2009/00281A patent/ZA200900281B/en unknown
- 2009-02-04 CO CO09010534A patent/CO6180465A2/es active IP Right Grant
- 2009-02-11 NO NO20090662A patent/NO341949B1/no not_active IP Right Cessation
-
2010
- 2010-02-10 HK HK10101501.8A patent/HK1135091A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
JP5266219B2 (ja) | 2013-08-21 |
PL2046762T3 (pl) | 2011-07-29 |
WO2008010934A2 (fr) | 2008-01-24 |
HK1135091A1 (en) | 2010-05-28 |
DE602007012552D1 (de) | 2011-03-31 |
NO20090662L (no) | 2009-03-26 |
CA2657776C (fr) | 2013-08-27 |
NO341949B1 (no) | 2018-02-26 |
KR20090053779A (ko) | 2009-05-27 |
NZ574759A (en) | 2010-10-29 |
KR101433392B1 (ko) | 2014-08-29 |
CO6180465A2 (es) | 2010-07-19 |
AU2007275873A1 (en) | 2008-01-24 |
EA015710B1 (ru) | 2011-10-31 |
IL196409A0 (en) | 2009-11-18 |
PT2046762E (pt) | 2011-05-23 |
EA200900168A1 (ru) | 2009-06-30 |
ZA200900281B (en) | 2010-02-24 |
MX2009000395A (es) | 2009-01-29 |
EP2046762B1 (fr) | 2011-02-16 |
CA2657776A1 (fr) | 2008-01-24 |
AU2007275873B2 (en) | 2012-06-14 |
DK2046762T3 (da) | 2011-05-09 |
WO2008010934A3 (fr) | 2008-03-27 |
IL196409A (en) | 2016-03-31 |
ATE498615T1 (de) | 2011-03-15 |
EP2046762A2 (fr) | 2009-04-15 |
UA98304C2 (uk) | 2012-05-10 |
BRPI0714407A2 (pt) | 2013-03-05 |
JP2010504908A (ja) | 2010-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA30690B1 (fr) | Triazolyle phenyle benzenesulfonamides | |
WO2008008374A3 (fr) | Inhibiteurs de ccr2 et leurs procédés d'utilisation | |
HK1131134A1 (en) | Triazolyl pyridyl benzenesulfonamides as ccr2 or ccr9 modulators for the treatment of atherosclerosis | |
MX2007008474A (es) | Sulfonamidas de heteroarilo y ccr2. | |
WO2008008431A3 (fr) | Hétéroaryle sulfonamides et ccr2/ccr9 | |
BRPI0813695A2 (pt) | Heteroaril piridil e fenila benzenossulfonamidas fundidas como moduladores de ccr2 para o tratamento de inflamação | |
DE60318740D1 (de) | Bisarylsulfonamide | |
DE60328690D1 (de) | 1-aryl-4-substituierte piperazin-derivate zur verwendung als ccr1-antagonisten zur behandlung von entzündungen und immunerkrankungen | |
CO6290757A2 (es) | N-(2(hetarl)ari)arilsulfonamidas y n-(2-(hetaril)hetaril)arilsulfonamidas | |
CA2865714C (fr) | Sulfonamides de pyrazol-1-yl benzene convenant comme antagonistes de ccr9 |